• Drug: Prevymis (letermovir)
  • Manufacturer: Merck

  • Route of Administration: Oral

  • Site of Care: Outpatient
  • Approved Indication:

    • prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogenic hematopoietic stem cell transplant
    • prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-])
  • Disease: post-transplant cytomegalovirus (CMV) prophylaxis

  • Therapeutic Area: Infectious disease

  • Enrollment Form Link: merckaccessprogram-prevymis.com
  • Phone Number: 855-404-5278
  • Fax Number: 866-866-4127
  • Product Website: prevymis.com